Not Advent development, Sawston costs and development. Sawston is a company asset. It will likely go the typical accounting route, but looks like the company is not asking for the full 250,000 up front and is asking for some up front and the selling on a per dose basis to make it more manageable for patients from one of the patient posts. Thus it would likely not look like a lot up front given how there are not many patients likely going this route even in the U.K. it’s quite expensive. But even so, the company appears to have made an effort to make the up front costs less. Once it is licensed for marketing, then, the costs could probably be covered by various potential U.K. programs.
Market Data 
Markets 
AI
